<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335699">
  <stage>Registered</stage>
  <submitdate>8/07/2010</submitdate>
  <approvaldate>7/12/2010</approvaldate>
  <actrnumber>ACTRN12610001076066</actrnumber>
  <trial_identification>
    <studytitle>Repeat prostate evaluation and therapy pilot study in patients undergoing high dose rate brachytherapy for prostate cancer</studytitle>
    <scientifictitle>A pilot study to evaluate tolerance, safety and efficacy of repeated prostate biopsy in patients undergoing high dose rate brachytherapy for prostate cancer</scientifictitle>
    <utrn />
    <trialacronym>RePEAT Pilot</trialacronym>
    <secondaryid>Peter MacCallum Cancer Centre 10-68</secondaryid>
    <secondaryid>PMCC 10/68</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Repeated prostate biopsies are to be obtained from malignant areas identified on previous transrectal ultrasound biopsy. These will be prior to the first high dose rate (HDR) brachytherapy fractions and at various durations prior to the second HDR dose, and again approximately 30 minutes after that dose (i.e. up to 5 biopsies in total).</interventions>
    <comparator>NA</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Unacceptable Toxicity Rate - a composite measure of infection (requiring &gt;5 days of antibiotics), patient tolerance (refusal of subsequent biopsy) and grade 3 toxicity (using NCI CTC criteria)</outcome>
      <timepoint>6 weeks following intervention completion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>presence of prostate tissue on each biopsy assessed using light microscopy</outcome>
      <timepoint>6 weeks following intervention completion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients undergoing high dose rate brachytherapy for prostate cancer</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>previous transurethral resection of prostate (TURP), anticoagulation, previous sepsis from prostate biopsy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>13</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Peter MacCallum Cancer Centre</primarysponsorname>
    <primarysponsoraddress>St Andrews Pl
E Melbourne
VIC 3000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Prostate Cancer Foundation of America (PCF)</fundingname>
      <fundingaddress>Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, CA 90401</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress>NA</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>a preliminary study of the ability to obtain tissue before and after radiation therapy (using brachytherapy) for the purpose of studying the molecular and cellular response of the cancer.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>St Andrew Pl
E Melbourne
VIC 3000</ethicaddress>
      <ethicapprovaldate>11/10/2010</ethicapprovaldate>
      <hrec>10/68</hrec>
      <ethicsubmitdate>6/08/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Scott Williams</name>
      <address>Peter MacCallum Cancer Centre
St Andrews Place
E Melbourne
VIC 3000</address>
      <phone>+61 3 9656 1111</phone>
      <fax>+61 3 9656 1424</fax>
      <email>scott.williams@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Scott Williams</name>
      <address>Peter MacCallum Cancer Centre
St Andrews Place
E Melbourne
VIC 3000</address>
      <phone>+61 3 9656 1111</phone>
      <fax>+61 3 9656 1424</fax>
      <email>scott.williams@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Scott Williams</name>
      <address>Peter MacCallum Cancer Centre
St Andrews Place
E Melbourne
VIC 3000</address>
      <phone>+61 3 9656 1111</phone>
      <fax>+61 3 9656 1424</fax>
      <email>scott.williams@petermac.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>